GLENMARK.NS Profit & Loss
Glenmark Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 22:31
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹12,990.11 Cr. | ₹11,813.10 Cr. | ₹13,321.74 Cr. | ₹16,982.51 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹316.79 Cr. | ₹839.99 Cr. | ₹113.72 Cr. | ₹460.62 Cr. | OtherIncome |
| Total Income | ₹13,306.90 Cr. | ₹12,653.09 Cr. | ₹13,435.46 Cr. | ₹17,443.13 Cr. | Income |
| Cost of Materials Consumed | ₹3,593.79 Cr. | ₹3,157.82 Cr. | ₹3,001.27 Cr. | ₹2,961.46 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹1,268.26 Cr. | ₹1,451.17 Cr. | ₹1,566.00 Cr. | ₹2,396.64 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-325.09 Cr. | ₹-195.62 Cr. | ₹-213.93 Cr. | ₹-610.64 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹2,780.96 Cr. | ₹2,868.14 Cr. | ₹3,022.06 Cr. | ₹3,577.85 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹349.58 Cr. | ₹515.97 Cr. | ₹207.06 Cr. | ₹208.72 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹611.27 Cr. | ₹581.91 Cr. | ₹486.01 Cr. | ₹573.48 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹3,393.83 Cr. | ₹3,336.25 Cr. | ₹3,594.96 Cr. | ₹4,084.78 Cr. | OtherExpenses |
| Total Expenses | ₹11,672.59 Cr. | ₹11,715.64 Cr. | ₹11,663.43 Cr. | ₹13,192.30 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹1,634.31 Cr. | ₹937.45 Cr. | ₹1,772.03 Cr. | ₹4,250.83 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-765.85 Cr. | ₹-900.96 Cr. | ₹-372.82 Cr. | ₹-2,266.08 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹868.45 Cr. | ₹36.49 Cr. | ₹1,399.21 Cr. | ₹1,984.75 Cr. | ProfitBeforeTax |
| Tax Expense | ₹491.05 Cr. | ₹1,867.35 Cr. | ₹352.07 Cr. | ₹622.79 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹377.40 Cr. | ₹-1,433.52 Cr. | ₹1,047.14 Cr. | ₹1,361.95 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹0.00 Cr. | ₹-1,501.67 Cr. | ₹1,047.10 Cr. | ₹0.10 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹10.53 | ₹-53.22 | ₹37.11 | ₹48.26 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹10.53 | ₹-53.22 | ₹37.10 | ₹48.24 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from GLENMARK.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).